SRR1516085
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- HEDGEHOG_SIGNALING+0.460
- IL6_JAK_STAT3_SIGNALING+0.460
- ALLOGRAFT_REJECTION+0.420
- INFLAMMATORY_RESPONSE+0.370
- UV_RESPONSE_DN+0.330
- APICAL_JUNCTION+0.300
- IL2_STAT5_SIGNALING+0.300
- MYOGENESIS+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- MYC_TARGETS_V1-0.620
- E2F_TARGETS-0.510
- OXIDATIVE_PHOSPHORYLATION-0.450
- G2M_CHECKPOINT-0.430
- MTORC1_SIGNALING-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.330
- DNA_REPAIR-0.320
- GLYCOLYSIS-0.310
- FATTY_ACID_METABOLISM-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278881 | — | — | 0.930 |
| 2 | R163 | — | — | 0.930 |
| 3 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.930 |
| 4 | TCGA-AC-A3HN-01A-11R-A213-07 | — | A | 0.926 |
| 5 | 20020074.LumA | — | A | 0.925 |
| 6 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.922 |
| 7 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.918 |
| 8 | be2c2361-72eb-4810-9068-4625b4ba0088 | — | — | 0.916 |
| 9 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.915 |
| 10 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.460 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |